Celcuity (NASDAQ: CELC) is one of 23 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its peers? We will compare Celcuity to related businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, profitability and institutional ownership.

Risk and Volatility

Celcuity has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Celcuity’s peers have a beta of 1.33, suggesting that their average share price is 33% more volatile than the S&P 500.

Profitability

This table compares Celcuity and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celcuity N/A -24.34% -23.67%
Celcuity Competitors -103.54% -222.38% -36.27%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Celcuity and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celcuity 0 0 2 0 3.00
Celcuity Competitors 138 571 678 36 2.43

Celcuity currently has a consensus price target of $35.50, indicating a potential upside of 42.28%. As a group, “Medical laboratories” companies have a potential upside of 16.05%. Given Celcuity’s stronger consensus rating and higher possible upside, equities analysts plainly believe Celcuity is more favorable than its peers.

Earnings & Valuation

This table compares Celcuity and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Celcuity N/A -$6.25 million -31.99
Celcuity Competitors $1.13 billion $90.54 million 433.94

Celcuity’s peers have higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

15.2% of Celcuity shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Medical laboratories” companies are owned by institutional investors. 43.5% of Celcuity shares are owned by insiders. Comparatively, 16.7% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Celcuity beats its peers on 7 of the 13 factors compared.

Celcuity Company Profile

Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.